Disease prediction models are clinically valuable when they accurately assess the risk of having the condition in future, 3 and have an impact on clinical decision-making, patient outcomes and health costs. [5] [6] [7] [8] [9] [10] In medical research, predictive tools can be used to screen and stratify patients for experimental studies, based on their risk of having the health outcome of interest. 4 Such models have clinical utility when they are able not only to distinguish patients with and without the disease with high accuracy, but also when their performance is reproducible across different populations and clinical settings. 11 In this context, it is necessary to test and validate predictive models in external studies, using different populations with comparable characteristics and similar clinical settings, as this enables the quantification of their predictive ability and an assessment of their generalizability. 6, 7, 12 The appropriate specification of the target population for external validation is crucial in the assessment of the validity and clinical utility of predictive models.
The importance of validation has been demonstrated many times in different fields of medical research, 13, 14 and a significant reduction in the predictive ability of a model when applied to a new dataset has been consistently reported. 14 Despite this, few studies have attempted to validate their models in different populations and settings; methods for internal, or "apparent," validation are commonly used, but these approaches can lead to over-optimistic results. 6, 8, 12, 15 Many prediction tools have been proposed to forecast asthma in children from the general population [16] [17] [18] [19] [20] and high-risk groups, [21] [22] [23] [24] [25] [26] [27] [28] but their predictive performance, clinical usefulness and reproducibility in external populations are limited, making them difficult to use in clinical practice and/or research. 29, 30 Despite lack of validation and uncertainty of predictive performance in different populations, the
U.S. National Asthma Education and Prevention Program Expert
Panel Report 3 (EPR-3) recommends the use of a modified Asthma predictive index (API). 31 In contrast, two recent comprehensive systematic reviews 29, 30 concluded that none of the existing models can robustly predict or rule out persistent asthma. These reviews focused on development studies, without exploring the reliability and usefulness of the predictive tools in different populations and clinical settings. In the current study, we focused on validation studies together with the original development studies and assessed their statistical methods, predictive abilities and clinical usefulness in children from both the general population and high-risk groups.
2 | ME TH ODS
| Search strategy and selection criteria
We focused only on studies which externally validated existing asthma predictive tools, alongside the studies in which they were originally developed. Our methods were based on the CHecklist for critical
Appraisal and data extraction for systematic Reviews of prediction Modelling Studies (CHARMS) 32 and the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statements. 33 The protocol was registered on PROSPERO (CRD42016035727).
An electronic search was performed on 11 July 2017 by a search of two databases, MEDLINE and EMBASE, using both free text and MESH terms. The search strategies are supplied as Supporting Information ( Figures S1 and S2 ). In addition, further studies were traced through cross-checking of reference lists from identified relevant papers. Studies of all designs were included only when they: (a) investigated the prediction of asthma in external validation studies and in original studies that had developed the validated tools; (b) performed outcome assessment in children between the ages of 6 and 18; (c) tested at least three candidate predictors in the model development; (d) evaluated at least one performance measure, including overall accuracy, discrimination and calibration measures;
(e) were written in English. We excluded letters, editorials and conference papers. Overall, more than 900 papers were identified as potentially eligible; these were screened for eligibility based on title, abstract and full text when necessary, by two independent reviewers (SC and DM). The reason for exclusion was recorded; a flow diagram of our selection process is displayed in Figure 1 .
| Data extraction
Data extraction was performed in duplicate by two reviewers (SC and DM) using a form developed with the CHARMS checklist. 32 The reviewers resolved any discrepancies through discussion with two other authors (CM and PC), until a consensus was reached. We extracted performance measures and calculated predictive values and likelihood ratios (LR) if they were not reported.
3 | RESULTS
| Target population
Studies that aimed to identify children who will have asthma in later life could be grouped into two main categories: (a) studies of the general population (with two studies recruiting participants at birth 16, 19 and four approaching generally healthy children recruited through healthcare practices, schools or local registries 17, 18, 34, 35 ); and (b) studies in children at "high risk" of persistent asthma (with two studies recruiting infants born to allergic parents, 24, 26 eight studies approaching symptomatic children recruited at healthcare practices or schools [21] [22] [23] 25, 34, [36] [37] [38] and a single study looking at children attending hospital with asthma symptoms). 27 In total, only three prediction tools were externally validated and therefore considered in this review: (a) the Asthma Predictive Index (API), 16 which was validated in two studies 35, 36 ; (b) the Prevention and Incidence of Asthma and Mite Allergy (PIAMA) tool, 23 which was validated in one study, 34 with a further study assessing the predictive capabilities of both API and PIAMA tool 37 ; (c) a simple asthma prediction tool developed by Pescatore et al, 19 which was validated in one study. 38 We reviewed these five validation studies [34] [35] [36] [37] [38] and the three related development studies. 16, 19, 23 The API was the only tool developed in a general population, while most of its validation studies were undertaken in high-risk children. 
| Predictors
In total, 16 different candidate predictors were used in the models'
development. All models included a history of self-reported or doctor-diagnosed eczema, the presence of wheeze aside from colds and a measure of the frequency of early wheezing. Other variables included gender, 19, 23 age, 19 allergic rhinitis and self-reported or doctor-diagnosed parental asthma. 16, 19 The full list of predictors used in the development models is available in Table 2 . While a wide variety of predictors has been tested, no studies examined the same combination. Aside from blood eosinophilia, 16 other potential objective measurements (eg total and specific IgE levels, skin prick tests) were not considered. Environmental exposures such as crowding, indoor pollution and pets in the house, potentially associated with asthma development, 39 were not included in the models assessed.
| Outcome definition
There was, among the development studies, heterogeneity in the way researchers defined the primary outcome (Table S1 ). The most commonly used criterion was wheezing in the previous 12 months. To define asthma for the API, Castro-Rodriguez et al 16 used a combination of doctor-diagnosed asthma and at least one wheezing episode in the last 12 months, or three or more episodes of wheeze regardless of a doctor's diagnosis. In the PIAMA study, Caudri et al defined childhood asthma at age of outcome assessment based on any of the following: at least one wheezing episode in the last 12 months, doctor diagnosis of asthma or asthma medication between the ages of 7 and 8 years. 23 The risk score developed by Pescatore et al defined asthma as a combination of wheezing and asthma medication in the last 12 months. 19 No objective measurements (eg lung function tests)
were used to assess asthma in any of the development studies.
While some validation studies 37, 38 defined outcomes using the same criteria as in the development study, others modified them. In the validation of the API, one study increased the required number of wheezing episodes in the preceding 12 months from three to four, 35 while another 36 used a different combination of criteria (Table S1 ).
Hafkamp-de Groen et al 34 did not have data on asthma medication at the age of outcome assessment and validated the PIAMA index using the definition of asthma from Leonardi et al. 35 The age at outcome assessment varied across the development studies, with the API providing asthma prediction from 6 and up to 13 years, 16 while other tools examined the outcome only up to the age of 8. The validation studies assessed asthma at an age which was 1 or 2 years different from the age in the development studies.
| Statistical modelling and predictive performance
Statistical approaches used to develop the predictive models in the development studies included the chi-square test to compare Table S2 .
The reporting of performance measures in the development and validation studies varied. The discriminative ability measured by the area under the ROC curve (AUC) was reported in five studies (two development 19, 23 and three validation studies 34, 35, 38 ) and ranged between 0.63 and 0.83 (Table S3 ). In general, predictive models with high sensitivity had lower specificity, and discrimination measures were better in studies in high-risk groups with a higher prevalence of outcome, compared to those in the general population. Likelihood ratios (LR) are additional measures of diagnostic accuracy and indicate the probability of a subject having, or not, the condition given the results of a predictive model. Overall, LRs were not reported in development studies; only two validation studies calculated these performance measures without providing their confidence intervals. We calculated point estimates of LRs to attempt a comparison among prediction models; however, the lack of confidence intervals may lead to misinterpretation of results and predictive performance.
The models with higher positive LR, at the same time, resulted in a higher negative LR (Figure 2 ). Positive LR varied between 1.07 and 7.43, and negative LR between 0.26 and 0.88. The highest LR were reported in the "stringent" API development study. 16 The performance of the tools varied at different ages of outcome assessment ( Figure 3A1 ,A2 and Table S3 ). The "stringent" and "loose" versions of the API used in validation studies showed higher sensitivity compared to the original study.
The maximum values were reported in the studies carried out in a high-risk population, but had similar or lower specificity in the external validation studies at all age groups. All externally validated studies of the API reported much wider confidence intervals for the performance measurements compared to the development study (Table S3 ).
The PIAMA index has been externally validated in two studies, with only one providing most performance measures. The original PIAMA study 23 showed higher sensitivity and positive LR, similar specificity and much lower positive predictive value at the age of 7-8 years when compared with the study reported by Rodriguez-Martinez et al, which assessed children at 5-6 years 37 ( Figure 3B and Table S3 ).
A predictive score developed by Pescatore et al 19 was validated in a single study, 38 which showed, at the age of 8, higher sensitivity, positive LR and AUC with a similar specificity and lower positive predictive value compared to the development study which assessed childhood asthma between the age of 6 and 8 years ( Figure 3B and Table S3 ).
| Risk of bias
The risk of bias (Table S4) was assessed using the CHARMS checklist, 32 using previously reported criteria. 30 The risk of participant selection bias was low in all the studies but one. 37 The risk of bias for predictors and outcome assessment was low in all development and validation studies. Loss to follow-up resulted in a moderate attrition for seven studies out of eight; the risk of attrition bias was high in Rodriguez-Martinez and co-authors' study as loss to follow-up was higher than 20% and differences on key characteristics between participants and those who were lost to follow-up were not fully described. Half of the studies provided relevant aspects of the analysis resulting in a low risk of analysis bias, 19 Likelihood ratios are useful in clinical practice as they allow physicians to calculate the probability of disease for specific patients by directly relating pre-test and post-test probabilities. Calculation of the post-test probability and comparison between pre-and post-test probabilities can also be assessed using the Fagan's nomogram which is a graphical tool where a straight line drawn from a patient's pretest probability of condition (left axis) through the LR of the test (middle axis) is intersected with the post-test probability of disease (right axis). In general, the higher the pre-test probability or prevalence, the higher is the post-test probability. The European Academy of Allergy and Clinical Immunology (EAACI) suggests using a LR interpretation of IgE sensitization tests, 40 and a similar approach may be used for asthma predictive tools.
Leonardi et al, 35 Devulapalli et al 36 The variation in the predictive performance between development and validation studies can be explained by artefactual and clinical mechanisms. 41 Artefactual mechanisms refer to performance variability arising from flaws in the design and execution of the validation studies; these include misspecification of the target population in terms of inclusion criteria for the enrolment of participants, poor data reporting, application of inappropriate statistical analysis and lack of a standardization in asthma definition. 42 The use of selfor proxy-reported questionnaires to establish asthma diagnosis is an important drawback of the included predictive models. It may lead to over-diagnosis of asthma, as a single episode of wheeze per annum reported by parents without any supportive clinical information may not accurately describe asthma. Recent data show that asthma is often over-diagnosed even in clinical settings, 43 with parental reported medical history of cough and wheeze being the main reasons behind inaccurate diagnosis. This shows that self-or proxyreported information has limited reliability as part of asthma definition, highlighting the importance of objective measurements and potentially explaining the difference in asthma prevalence in the studies assessed. However, no objective measurements were used to characterize asthma in both development and validation studies.
Possible clinical mechanisms include "case-mix variation", [44] [45] [46] which is a special type of the "spectrum effect"; the latter describes the variation in sensitivity, specificity and accuracy among different populations and subgroups, [47] [48] [49] while case-mix variation refers to differences between development and validation studies in clinical settings, subject characteristics, age of outcome assessment, outcome prevalence and/or incidence. 44 In particular, the larger the difference between the characteristics of the original and external validation populations, the higher the discrepancy in predictive performance and the poorer the generalizability of findings.
Sensitivity, specificity and likelihood ratios are generally used as benchmarks for comparison of model performance as they are thought to be independent of the prevalence of the outcome, [50] [51] [52] while predictive values vary with the prevalence of the disease. However, several studies have shown that sensitivity and specificity, Among three models reviewed Pescatore, prediction tool was the only one validated using exact parameters of original instrument. Authors of some API validation studies made some changes to API criteria, which potentially could influence instrument predictive abilities.
Differences in age of outcome assessment can also lead to casemix variation and change in predictive performance. Prediction is usually challenging, and predictive performance may be limited when the outcome is assessed later in future using information collected very early in life. The majority of existing studies on childhood asthma prediction aimed to develop and validate asthma predictive tools between 6 and 10 years of age using predictors collected at 3-5 years of life, making prediction potentially relatively simple and reliable. The validation studies assessed asthma at a similar age to their development counterparts leading to comparable results, but it is notable that no studies have aimed to develop and externally validate asthma predictive models beyond the age of 13 years.
At the present, asthma is considered an "umbrella term", 55 bringing together a selection of different conditions that share common clinical features such as cough and wheeze, shortness of breath and bronchial obstruction. 56 While the concept of distinct wheezing and asthma endotypes has been proposed, existing guidelines based on clinical symptoms and predictive models are still aimed at a single disease. 57 This may partially explain the inaccuracy of asthma prediction models; future work should consider endotypes to a larger extent in the development of predictive models. Another important issue, potentially affecting predictive performance, is individual genetic predisposition to disease development. This important factor was not taken into account in the development and validation studies included in this systematic review.
With more research coming from genome-wide association studies (GWAS), genetic variants that predispose individuals to asthma have been identified 58 ; for example, a meta-analysis of GWAS reported seven asthma genetic risk loci (HLA-DQ, IL33, ORMDL3/ GSDMB, IL1RL1/IL18R1, IL2RB, SMAD3 and TSLP). 59, 60 Considering these in the development of future predictive models may lead to improved predictive performance.
To provide better assessment of the predictive ability of existing asthma prediction models, future research should aim at collecting information using well-standardized questionnaires and clinical tests to allow for better harmonization of predictor and outcome definitions. Collaborative international, multi-centre efforts would offer the opportunity to increase sample size, and to develop predictive models using information from subsets of studies and then validate them in the remaining ones. More studies run on general and high-risk populations in parallel will allow for meaningful evaluation of model performance. Clinical tests including lung function tests, SPTs, allergen-specific IgE, fractional exhaled nitric oxide (FeNO) and bronchodilator response might also be used to increase
(B)
F I G U R E 3 Performance measures among predictive tools the capability of a predictive tool to correctly identify children at high risk of asthma in later childhood and young adulthood. Moreover, external study populations should be carefully selected, with characteristics similar to those of the study populations where the predictive models were developed in order to have low heterogeneity within subpopulations.
In conclusion, validated tools for predicting childhood asthma provide poor predictive accuracy, with some performance variation in sensitivity and positive predictive value. Those available asthma predictive tools that have not been externally validated should be evaluated to assure their reliability. Larger cohorts are needed to include more predictors into the models and to use more advanced statistical methods. More work on standardization of predictors and outcome assessment needs to be done.
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